Fig. 2From: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecanKinase genes (PSKH1, TLK2 and PHKG2) that were differentially expressed between patients with and without the disease control to CIBack to article page